Sipp Industries Forges Distribution Agreement with SinuSave®'s CBD Nasal Spray
Sipp Industries, Inc., reaches a distribution agreement with SinuSave® regarding their SinuSave® CBD Nasal Spray products.
A recent press release disclosed that Sipp Industries, Inc., (Sipp Industries) has reached a distribution agreement with SinuSave® (1). This deal is in regard to SinuSave®’s patented cannabidiol (CBD) Nasal Spray products which are offered in two dosages, 500mg and 1000mg and is “bacteriostatic” and “bactericidal” (1). Additionally, the CBD nasal spray is formulated with a patented mixture of nine essential oils.
The cannabinoid, CBD, has become well-known to cannabis users for its pain relieving properties. The press release mentions that this cannabinoid might also be of help in relieving allergy, sinusitis, air pollution, and cold symptoms (1). Pertaining to daily nasal hygiene, the CBD nasal spray, is currently the only patented drug-free product created for this purpose.
“This partnership with SinuSave® represents an exciting leap forward for SIPP Industries,” Jakob Jorgensen, CEO of SIPP Industries, mentioned (1). “We are incredibly proud to align ourselves with a product that has the potential to transform the well-being of individuals seeking advanced, effective solutions for nasal health. The patent-pending, nano-emulsified CBD technology showcased in SinuSave's nasal spray is a game-changer, and we are thrilled to be at the forefront of its distribution.”
The Original SinuSave® nasal spray has been around since 2017 (1). Their new CBD product provides similar benefits with the addition of the medical properties the cannabinoid provides.
“The SinuSave® CBD Nasal Spray is set to revolutionize how individuals approach nasal health. With our distribution agreement with SIPP Industries, we are excited to reach more consumers and make a positive impact on their well-being,” Lou Lobel, President of SinuSave®, explained (1). “This strategic partnership is poised to empower consumers seeking alternative, natural solutions for nasal care. It showcases a shared commitment to innovation, quality, and excellence in the wellness landscape.”
According to Sipp Industries press release (1), the global nasal market was previously valued at $24.5 billion in 2022. Data from Verified Market Research foresees these numbers to increase at a compound annual growth rate (CAGR) of 6.7% (1).
Per the distribution agreement, Sipp Industries will be in charge of the distribution, sales,and marketing of SinuSave®’s CBD nasal spray products (1). The items from SinuSave®’s product lineup will be offered in retail stores and online soon. Sipp Industries is also investigating distributing SinuSave®’s products internationally as well.
Reference
- Sipp Industries, Inc. Sipp Industries Announces Distribution Agreement for Patented SinuSave® CBD Nasal Spray https://www.globenewswire.com/news-release/2024/01/23/2814273/0/en/Sipp-Industries-Announces-Distribution-Agreement-for-Patented-SinuSave-CBD-Nasal-Spray.html (accessed Jan 23, 2024).
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
